Pacira Biosciences, Inc. and Molteni Farmaceutici Announce Exclusive Agreement with Molteni Farmaceutici to Commercialize Exparel® in the European Union and United Kingdom
Pacira BioSciences, Inc. has partnered with Molteni Farmaceutici to commercialize EXPAREL® (bupivacaine liposome injectable suspension) in the European Union and United Kingdom. Under the exclusive agreement, Molteni will handle regulatory, market access, and commercialization activities, starting with launches in Italy, Germany, Austria, and Poland in 2027, while Pacira will manufacture the drug. This collaboration aims to expand access to opioid-sparing postsurgical pain management across European markets.
Pacira BioSciences partners with Molteni for European expansion By Investing.com
Pacira BioSciences has partnered with Molteni Farmaceutici to distribute its postsurgical pain management drug, EXPAREL, across European markets. Molteni will receive exclusive distribution rights and plans to launch the product sequentially, starting with Italy, Germany, Austria, and Poland, with the first commercial sale expected in 2027. Pacira also reported granting inducement awards to two new employees, including stock options and restricted stock units.
Pacira BioSciences partners with Molteni for European expansion By Investing.com
Pacira BioSciences has announced a partnership with Molteni Farmaceutici to expand the distribution of EXPAREL, its postsurgical pain management injectable, into European markets. Molteni will exclusively distribute and commercialize EXPAREL, with an initial launch planned for Italy, Germany, Austria, and Poland, and the first commercial sale expected in 2027. Additionally, Pacira granted inducement awards to two new employees, consisting of stock options and restricted stock units.
A postsurgery pain medicine is planned to launch in four countries; first sales are expected in 2027.
Pacira BioSciences has signed an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL, a postsurgical pain treatment, in the European Union and United Kingdom. Pacira will receive an upfront payment, supply payments, and royalties, while Molteni will handle commercialization and plans sequential launches starting in 2027 in Italy, Germany, Austria, and Poland. Additionally, Pacira granted inducement awards to two new employees consisting of stock options and restricted stock units.
Pacira BioSciences stock weighs Q2 growth and lower guidance
Pacira BioSciences (PCRX) reported Q2 2026 revenue of USD 192.4 million, exceeding expectations, but subsequently lowered its full-year revenue guidance due to the sale of iovera. Analysts maintain an "Outperform" consensus rating with price targets above the current stock price, suggesting potential upside despite the revised outlook. The stock closed 9.0 percent below its 52-week high, with a market capitalization of USD 991.6 million, presenting a valuation trade-off for investors.
Technical Reactions to PCRX Trends in Macro Strategies
Pacira Biosciences Inc. (NASDAQ: PCRX) is showing a neutral sentiment across all time horizons, suggesting sideways trading. The article outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. Key support and resistance levels are identified, with an exceptional 34.1:1 risk-reward setup targeting a 9.5% gain versus 0.3% risk.
Pacira: More Sales, Less Adjusted EBITDA, Better Cash
Pacira BioSciences reported a mixed second quarter with increased sales and substantially improved free cash flow, despite a decline in adjusted EBITDA. The company's recent divestiture of iovera complicates year-over-year comparisons, and future reports will need to demonstrate margin sustainability and cash conversion for the retained portfolio. Management's challenge is to prove that increased operating expenses will lead to durable returns and improved profitability.
Oppenheimer Initiates Pacira Biosciences at Outperform With $32 Price Target
Oppenheimer has initiated coverage on Pacira Biosciences (PCRX) with an Outperform rating and a $32 price target. This analyst action follows previous coverage initiations and price adjustments from other firms, highlighting ongoing analyst interest in the pharmaceutical company. Pacira BioSciences specializes in non-opioid pain management and is also developing a gene therapy for osteoarthritis.
Oppenheimer Initiates Pacira Biosciences at Outperform With $32 Price Target
Oppenheimer has initiated coverage of Pacira Biosciences (PCRX) with an "Outperform" rating and a $32 price target. This new rating is above the average analyst rating for PCRX, which is currently "overweight" with a mean price target of $29.67. The full MT Newswires article requires a premium subscription to read.
Pacira BioSciences stock falls 2.35 percent to USD 24.11
Pacira BioSciences (PCRX) stock fell 2.35% to USD 24.11 on September 21, 2026, closing with a market capitalization of USD 961.07 million. This decline occurred despite the Nasdaq Composite gaining 2.26% on the same day, marking a 4.61 percentage point underperformance for Pacira. The company, a specialty and generic drug manufacturer, saw its equity value remain near the USD 1 billion threshold.
ASA and Pacira BioSciences Strengthen Strategic Collaboration Focused on Education, Quality Improvement and Patient Outcomes | Newswise
The American Society of Anesthesiologists (ASA) and Pacira BioSciences, Inc. are expanding their strategic collaboration to enhance physician education, advocacy, quality improvement, and non-opioid pain management approaches. This partnership, built on three years of engagement, aims to improve patient outcomes through initiatives like supporting the NOPAIN for Veterans Act and reauthorization of the NOPAIN Act. Pacira will also participate in ASA's Center for Perioperative Medicine Corporate Advisory Council and host an interactive Satellite Symposium.
Five new employees receive Pacira stock awards, vesting over four years
Pacira BioSciences granted equity inducement awards to five new employees on September 2, 2026, under its Amended and Restated 2014 Inducement Plan. These awards, approved by the Board’s People & Compensation Committee without stockholder approval as per Nasdaq Listing Rule 5635(c)(4), include stock options for 8,900 shares and restricted stock units for 14,000 shares. The stock options have a 10-year term and a four-year vesting schedule, while the restricted stock units vest annually in four equal installments starting September 1, 2027, with both subject to continued employment.
ETFs Investing in Pacira Biosciences, Inc. Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Pacira Biosciences, Inc. stocks. The list is sorted by market value and includes various details such as weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return for each ETF. This information helps investors identify diversified opportunities with potentially lower risk.
Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX
Rice Hall James & Associates LLC recently acquired 93,396 shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) during the second quarter, valued at approximately $2.37 million, representing about 0.23% of the company. Other institutional investors have also adjusted their holdings, while company insiders have sold shares. Pacira BioSciences reported strong earnings, beating analyst estimates, and has received a consensus "Hold" rating from Wall Street analysts with an average target price of $30.20.
Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock
Pacira BioSciences insider Jonathan Slonin sold 3,040 shares of the company's stock for a total of $70,619.20. This transaction reduced his ownership by 1.39% to 216,384 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock traded up 3.3% to $24.00, and it recently beat EPS estimates with a revenue increase of 6.2% year-over-year.
Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan
Pacira BioSciences (PCRX) Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026, at $23.23 per share through an open-market transaction. This sale was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025. Following the transaction, Slonin directly holds 216,383.646 shares, which includes shares acquired via the company’s employee stock purchase plan.
Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026
Pacira BioSciences (NASDAQ: PCRX) is set to see a proposed sale of 3,040 common shares with an aggregate market value of $70,619.20 on August 17, 2026. The sale, detailed in a Form 144 SEC filing, will be executed through Fidelity Brokerage Services LLC on the NASDAQ market. The shares were originally acquired by the filer through an Employee Stock Purchase Plan and restricted stock vesting in mid-2022.
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial
Truist Financial initiated coverage on Pacira BioSciences (NASDAQ:PCRX) with a "buy" rating and a $30.00 price target, suggesting a 28.81% potential upside. This comes after Pacira BioSciences reported strong quarterly earnings, exceeding analyst estimates with $0.73 EPS and $192.4 million in revenue, a 6.2% increase year-over-year. Despite these positive developments and institutional investor interest, the company maintains a "Hold" consensus rating among analysts, with an average price target of $30.20.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Brokerages
Brokerages have issued a consensus "Hold" rating for Pacira BioSciences (NASDAQ:PCRX), with an average 12-month price target of $29.80 against its current price of $23.00. The company recently surpassed quarterly earnings estimates, reporting $0.73 EPS on $192.4 million in revenue. Institutional investors hold a significant 99.73% of the shares, while an insider recently sold a portion of their holdings.
Pacira Biosciences (NASDAQ:PCRX): A Value Play with Fundamentals Intact
Pacira Biosciences (NASDAQ:PCRX) is presented as a compelling value investment due to its strong valuation metrics, including low P/E and Price/Free Cash Flow ratios, despite a mixed but acceptable financial health and profitability profile. While growth has been a weaker point historically, analyst expectations for future EPS growth, combined with its strong free cash flow generation, suggest it may be an undervalued opportunity. Investors are cautioned to consider risks such as declining margins and a leveraged balance sheet.
Empowered Funds LLC Buys 49,171 Shares of Pacira BioSciences, Inc. $PCRX
Empowered Funds LLC significantly increased its stake in Pacira BioSciences (NASDAQ:PCRX) by 21.6% in the first quarter, acquiring 49,171 additional shares, bringing its total holding to 276,776 shares valued at $6.3 million. This increase contributes to institutional investors owning 99.73% of the company's stock. The news follows Pacira's strong Q1 earnings, where it surpassed analyst estimates with $0.73 EPS and a 6.2% year-over-year revenue increase, despite mixed analyst ratings and a recent insider stock sale.
Wedge Capital Management L L P NC Purchases New Stake in Pacira BioSciences, Inc. $PCRX
Wedge Capital Management L L P NC has acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX), purchasing 94,554 shares valued at approximately $2.4 million. This acquisition makes Wedge Capital a 0.24% owner of the company, which reports 99.73% institutional ownership. Pacira BioSciences recently exceeded quarterly EPS estimates and saw a 6.2% increase in revenue year-over-year, despite analysts maintaining a consensus "Hold" rating with a price target of $29.80.
Assenagon Asset Management S.A. Acquires Shares of 101,429 Pacira BioSciences, Inc. $PCRX
Assenagon Asset Management S.A. recently acquired 101,429 shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) valued at approximately $2.57 million, increasing institutional ownership to 99.73%. Despite a consensus "Hold" rating from analysts, the company exceeded Q2 expectations with $0.73 EPS and $192.4 million in revenue, an increase of 6.2% year-over-year. Insider activity shows SVP Lauren Riker selling 6,115 shares for $143,702.50 in June.
(PCRX) and the Role of Price-Sensitive Allocations
This article analyzes Pacira Biosciences Inc
Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data
Pacira BioSciences' stock (PCRX) fell 7.1% despite advancing its PCRX-201 gene therapy for knee osteoarthritis into Phase 2 following positive two-year Phase 1 data. The company also announced revised full-year revenue expectations of US$735 million to US$760 million, down from prior guidance, but reported a swing to profitability in Q2. Investors are weighing the long-term potential of the gene therapy pipeline against near-term financial pressures and execution risks.
Hennion & Walsh Asset Management Inc. Buys 48,124 Shares of Pacira BioSciences, Inc. $PCRX
Hennion & Walsh Asset Management Inc. increased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 31% in the second quarter, purchasing an additional 48,124 shares to now own 203,520 shares valued at approximately $5.16 million. Pacira recently reported strong quarterly earnings of $0.73 per share, surpassing consensus estimates, with revenue rising 6.2% year-over-year to $192.4 million. Analyst sentiment is mixed, with an overall "Hold" rating and an average price target of $29.80, though some analysts have raised their targets.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced inducement awards granted to five new employees on August 4, 2026, under its Amended and Restated 2014 Inducement Plan. These awards, approved by the People & Compensation Committee without stockholder approval in accordance with Nasdaq Listing Rule 5635(c)(4), include stock options for 8,500 shares and restricted stock units for 14,200 shares of Pacira common stock. The grants serve as a material inducement for their employment with the company.
Pacira BioSciences (NASDAQ:PCRX) Upgraded by Wall Street Zen to Strong-Buy Rating
Wall Street Zen has upgraded Pacira BioSciences (NASDAQ:PCRX) to a "strong-buy" rating from "buy," despite the broader analyst consensus remaining "Hold" with an average price target of $29.80. The company reported strong quarterly earnings, beating analyst estimates with EPS of $0.73 and revenue of $192.4 million, a 6.2% increase year-over-year. Institutional investors hold a significant 99.73% of the company's shares.
Press Release: Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced inducement grants of stock options and restricted stock units (RSUs) to seven new employees. These grants, totaling 19,850 stock options and 11,000 RSUs, were made outside the company's existing equity incentive plans as an inducement material to the new hires' employment in accordance with Nasdaq Listing Rule 5635(c)(4). The grants vest over four years, subject to continued employment.
State Street Corporation (NYSE: STT) discloses 5.2% ownership in Pacira BioSciences
State Street Corporation has disclosed a beneficial ownership of 2,059,977 shares, or 5.2%, of Pacira BioSciences Inc. common stock, as detailed in a Schedule 13G SEC filing. This filing indicates that State Street, along with its investment adviser subsidiaries, holds shared voting power over 1,944,697 shares and shared dispositive power over all 2,059,977 shares. The ownership is primarily for investment purposes, with no sole voting or dispositive power reported, meaning control is exercised jointly through entities like SSGA Funds Management, Inc. and various State Street Global Advisors affiliates.
Here's What Analysts Are Forecasting For Pacira BioSciences, Inc. (NASDAQ:PCRX) After Its Second-Quarter Results
This article examines the latest analyst forecasts for Pacira BioSciences, Inc. (NASDAQ:PCRX) following its second-quarter results. It provides an overview of the consensus earnings estimates and how they have changed over time, along with an assessment of the company's financial performance and future prospects according to market analysts. Investors can gain insights into the potential trajectory of PCRX based on these expert opinions.
Pacira BioSciences, Inc. $PCRX Shares Purchased by Pacer Advisors Inc.
Pacer Advisors Inc. increased its stake in Pacira BioSciences, Inc. by 24.5% in the first quarter, now owning 235,427 shares. The company reported strong Q2 revenue and EPS, exceeding analyst expectations, but its 2026 revenue guidance fell below consensus. Analyst sentiment is mixed, with some raising price targets and others maintaining a more cautious outlook, resulting in an overall "Hold" rating for the stock.
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
Pacira BioSciences announced the publication of positive two-year results from its Phase 1 clinical trial for PCRX-201, an investigational gene therapy for knee osteoarthritis, in the Annals of the Rheumatic Diseases. The study found that a single intra-articular injection of PCRX-201 was well-tolerated and showed improvements in pain, stiffness, and function for up to two years. The company is advancing PCRX-201 into its Phase 2 ASCEND trial, with initial topline data expected by year-end 2026.
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
Pacira BioSciences announced the publication of positive two-year Phase 1 data for its investigational gene therapy, PCRX-201, for knee osteoarthritis in the Annals of the Rheumatic Diseases. The study showed that a single intra-articular injection of PCRX-201 was well-tolerated and demonstrated sustained improvements in pain, stiffness, and function over two years. The company is advancing PCRX-201 into its Phase 2 ASCEND trial, with topline results expected by year-end 2026, and believes it has the potential to offer a long-lasting treatment for knee OA.
Pacira BioSciences, Inc. Stock 12‑Month Price Target Raised to $30, Implies 9% Upside
Pacira BioSciences, Inc.'s stock price target has been raised to $30 from $29.67 by 6 analysts, suggesting a 9% potential upside from its August 4 closing price. The consensus rating for PCRX remains a "Buy," with a breakdown of 3 Buys, 2 Holds, and 1 Sell among the analysts. Investors can explore more data and track recommendations on TradingView's platform.
Pacira BioSciences (NASDAQ: PCRX) earns Q2 profit and sells iovera business
Pacira BioSciences (NASDAQ: PCRX) reported a profit in Q2 2026 with total revenues of $192.4 million, driven by strong sales of EXPAREL and ZILRETTA. The company also announced the divestiture of its iovera° cryoanalgesia business to Zimmer for up to $140 million, including an upfront payment of $70 million. This strategic move aligns with Pacira's focus on innovative biopharmaceutical products and is expected to enhance its financial position, despite a decrease in interest income and a slight increase in operating expenses.
Pacira BioSciences (PCRX) Advances PCRX 201 As Its Undervalued Narrative Faces A Fresh Test
Pacira BioSciences (PCRX) has advanced its osteoarthritis gene therapy candidate, PCRX-201, to a scalable U.S. commercial manufacturing process and has begun enrolling patients in Part B of the Phase 2 ASCEND study. The company's shares are currently trading at US$26.92, which is significantly below its narrative fair value of $38.00, suggesting it is undervalued. Despite a 52.07% decline in total shareholder return over five years, the past year has shown improving momentum with a 19.43% return.
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Pacira BioSciences (PCRX) reported strong second-quarter 2026 results, beating analyst estimates for both earnings and revenues, driven by demand for Exparel, Zilretta, and iovera. Despite the strong performance, the company cut its 2026 sales outlook due to the divestiture of iovera, while maintaining other financial guidance. Pacira also secured a major win with UnitedHealthcare providing separate reimbursement for Exparel, expanding its covered lives.
Pacira BioSciences Q2 Earnings Call Highlights
Pacira BioSciences reported a 6% increase in Q2 2026 revenue to $192.4 million, driven by strong sales of EXPAREL, ZILRETTA, and iovera°. The company highlighted expanded payer coverage for EXPAREL and progress in its pipeline, while also completing the sale of iovera° to Zimmer Biomet. Pacira updated its full-year revenue guidance to reflect the divestiture but maintained its EXPAREL sales outlook, emphasizing growth from outpatient settings and commercial reimbursement.
RBC Adjusts Price Target on Pacira Biosciences to $25 From $24, Maintains Sector Perform Rating
RBC has increased its price target for Pacira Biosciences (PCRX) to $25 from $24, while maintaining a Sector Perform rating on the stock. This adjustment comes shortly after Pacira BioSciences reported its Q2 2026 earnings, posting an adjusted EPS of $0.73 per share against an estimated $0.65, and revenue of $192.4 million, exceeding the FactSet estimate of $191.1 million. The company also updated its earnings guidance for the full year 2026.
Pacira BioSciences Q2 2026 Earnings Call Transcript
Pacira BioSciences reported its Q2 2026 earnings, highlighting a 6% increase in total revenue to $192.4 million, driven by EXPAREL, ZILRETTA, and iovera° sales growth. The company successfully divested iovera° to Zimmer Biomet and lowered its full-year 2026 revenue guidance to $735 million-$760 million. Pacira emphasized strategic partnerships, pipeline advancements, and expanded commercial payer coverage for EXPAREL, including UnitedHealthcare, as key drivers for future growth despite a slowdown in certain elective soft tissue procedures.
Pacira Q2 2026 earnings: Revenue rises as adjusted EBITDA declines
Pacira BioSciences reported a 6% revenue increase to $192.4 million in Q2 2026, yet adjusted EBITDA declined by approximately 10% and non-GAAP net income fell 18% due to rising expenses. The company also lowered its full-year revenue guidance following the divestiture of iovera°. Despite a GAAP net income improvement, underlying operating profitability weakened, with EXPAREL remaining the primary revenue driver.
Pacira BioSciences, Inc. 2026: Revenue $192.4M, EPS $0.12— 10-Q Summary
Pacira BioSciences, Inc. reported strong financial results for the 2026 quarter, with revenue of $192.4M and diluted EPS of $0.12, showing significant growth compared to the prior year. Key drivers included increased net product sales for EXPAREL and ZILRETTA, expanded reimbursement for EXPAREL, and the divestiture of iovera° to Zimmer. The company also advanced its clinical pipeline and addressed potential risks related to supply chain and tariffs.
Pacira BioSciences Q2 Earnings Call Highlights
Pacira BioSciences (NASDAQ:PCRX) reported a 6% increase in second-quarter revenue to $192.4 million, driven by strong sales of EXPAREL, ZILRETTA, and iovera°. The company completed the sale of iovera° to Zimmer Biomet for up to $140 million and updated its full-year revenue guidance to $735 million-$760 million. Pacira anticipates three key clinical readouts by year-end, focusing on its non-opioid pain management pipeline.
Pacira BioSciences Q2 revenue rises 6% to $192.4 million
Pacira BioSciences reported a 6% increase in Q2 2026 revenue, reaching $192.4 million, with GAAP net income of $4.7 million. The company completed the divestiture of its iovera° business and updated its full-year revenue guidance to $735 million to $760 million. Insider trading activity showed sales by officers, while institutional investors had mixed movements in their holdings.
Earnings Flash (PCRX) Pacira BioSciences, Inc. Posts Q2 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.65
Pacira BioSciences, Inc. (PCRX) announced its Q2 adjusted EPS was $0.73 per share, surpassing the FactSet estimate of $0.65. The company also reported Q2 revenue of $192.4 million, exceeding the FactSet estimate of $191.1 million, and provided updated earnings guidance for the full year 2026. Additionally, RBC adjusted its price target for Pacira BioSciences to $25 from $24, maintaining a Sector Perform Rating.
Pacira BioSciences Reports Second Quarter 2026 Financial Results
Pacira BioSciences reported solid financial results for the second quarter of 2026, with total revenue reaching $192.4 million, a 6% year-over-year increase. The company highlighted progress on its 5x30 strategy, including the divestiture of its iovera® business, expanded reimbursement for EXPAREL® by UnitedHealthcare, and advancement of its PCRX-201 development program. Pacira also updated its full-year 2026 financial guidance to reflect the iovera® divestiture.
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
Pacira BioSciences released findings from its "Standing Strong: The Impact of Pain on America's Workforce" survey, highlighting that 85% of workers in physically demanding jobs experience pain while working, with chronic knee pain being a prevalent issue. The survey revealed significant impacts on income, career advancement, and quality of life, alongside a strong interest in long-lasting, non-opioid pain management options among those with chronic knee pain, even though 24% currently use prescription opioids. The company emphasized the need to raise awareness about effective non-opioid alternatives to help workers manage pain and improve their quality of life.
Pacira Biosciences Inc (PCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Pacira Biosciences Inc (PCRX), detailing its current risk score, beta value, and various volatility metrics. The company ranks 49th out of 155 in the pharmaceuticals industry with a risk assessment score of 6.68 and a beta of 0.30, indicating lower volatility compared to the S&P 500. The report also includes data on maximum drawdown, Sharpe Ratio, and liquidity.
Pacira BioSciences Advances PCRX-201 Development Program
Pacira BioSciences announced the successful transition of its PCRX-201 gene therapy for osteoarthritis of the knee to a scalable commercial manufacturing process, enabling the enrollment of the first patient in Part B of the Phase 2 ASCEND study. This development supports the company's 5x30 growth strategy and advances a key pipeline program. Topline data from Part A of the ASCEND study is still expected by the end of 2026.
